CT-guided Percutaneous Radionuclide Therapy With 32P Microparticles in Patients With Non-progressive Locally Advanced Pancreatic Cancer

NCT07595835 | Recruiting Phase 1 DMC

• 1 other identifier: NL78596.000.22
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Pancreatic ductal adenocarcinoma is a highly lethal cancer, and approximately 40% of patients present with non-metastatic locally advanced pancreatic cancer (LAPC) that is not suitable for surgical resection. To improve outcomes in this patient group, local ablative treatments are being explored. Radionuclide therapy (RNT) is a promising option that delivers high-dose internal radiation directly into the tumor, potentially achieving better local tumor control while sparing surrounding tissues compared with external-beam radiation therapy. The OncoSil™ device is a type of RNT containing Phosphorus-32-radiolabeled microparticles. The ³²P microparticles have been designed to deliver a localized distribution of beta-radiation within the target tumor up to 100 Gy, which causes direct damage to cancer cell DNA and renders them incapable of further cell division and proliferation. Favorable results have been reported by implanting ³²P microparticles intra-tumorally, which is typically administered via endoscopic ultrasound guidance. A percutaneous approach may allow for more precise and reproducible delivery, but prospective data on its safety and feasibility are lacking. This prospective, single-arm phase 1-2 feasibility study aims to evaluate the safety and feasibility of percutaneous CT- guided RNT using ³²P microparticles in patients with non-progressive LAPC following induction chemotherapy. Twenty adult patients with pathology-confirmed LAPC, showing non-progressive disease according to RECIST, will be included after multidisciplinary tumor board review. Patients will undergo percutaneous, CT-guided implantation of ³²P microparticles under general anesthesia, sedation, or local analgesia depending on study phase and clinical judgment, followed by continuation of standard systemic chemotherapy and routine follow-up. The primary endpoint is the rate of adverse events (CTCAE grade ≥3) occurring during the procedure and within 90 days afterward. Secondary endpoints include technical success, all adverse events, best overall respons, overall and progression-free survival, and changes in tumor markers.

Conditions

Pancreatic Cancer

Keywords

radionucleide therapy; brachytherapy; P32; internal radiotherapy; LAPC; ³²P microparticles; Oncosil

Outcome Measures

Primary Outcomes (1)

• Safety defined as the rate of procedure- or device-related CTCAE grade ≥3 adverse events (AEs) within 90 days after implantion.

  From implantation to 90 days after implantation

Secondary Outcomes (8)

• Technical succes defined a the rate of adequate punctures and subsequent complete intratumoral delivery of the planned dose.

  Periprocedural.

• Overall safety defined as the rate of adverse events.

  From implantation until 90 days after implantation.

• Duration of implantation procedure defined as the total time of punction.

  Periprocedural.

• Duration of overall procedure defined as the total time in the radiology suite.

  Periprocedural.

• Overall survival

  Defined from diagnosis and from implantion untill death by any cause, assessed up to end of study or up to 1 year after implantation.

Study Arms (1)

CT-guided percutaneous intratumoural implantation of ³²P microparticles for LAPC

EXPERIMENTAL

CT-guided percutaneous intratumoural implantation of the OncoSil™ device, containing ³²P microparticles as a form of radionucleide therapy for 20 patients diagnosed with RECIST-stable LAPC after 2 months of systemic therapy.

Device: CT-guided percutaneous intratumoural implantation of the OncoSil™ device

Interventions

CT-guided percutaneous intratumoural implantation of the OncoSil™ device DEVICE

CT-guided percutaneous intratumoural implantation of the OncoSil™ device, containing ³²P microparticles as a form of radionucleide therapy for 20 patients diagnosed with RECIST-stable LAPC after 2 months of systemic therapy.

CT-guided percutaneous intratumoural implantation of ³²P microparticles for LAPC

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age ≥18 years
• Locally advanced pancreatic cancer, defined by the DPCG consensus criteria as: arterial involvement \>90 degrees or venous involvement \>270 degrees.
• At least RECIST stable disease after a minimum two months of chemotherapy according to current clinical practice\*
• Capable of providing written and oral informed consent
• Candidate for RNT, judged by a multidisciplinary tumor board
• WHO 0-2

You may not qualify if:

• Eligibility for resection
• Participation in other trials focussing on different ablative treatment modalities such as radiofrequency ablation or irreversible electroporation for LAPC
• Known hypersensitivity to silicon or phosphor
• Bleeding disorders which cannot be corrected with medication
• Inability/unwillingness to interrupt anticoagulation therapy
• Pregnancy
• Metastatic pancreatic cancer
• Epilepsy episode(s) in the past six months
• Longest tumor diameter \>70 mm or total target tumor volume \>110 ml
• Presence of multiple collateral vessels surrounding or adjacent to the target tumor on radiologic imagining, prohibiting safe injection of the OncosilTM device
• Presence (or significant risk) of varices near the target tumor on radiologic imaging
• Recent clinically significant pancreatitis
• Previous administration of radiotherapy to the pancreas

Sponsors & Collaborators

• M.R. Meijerink: lead

Study Sites (1)

Amsterdam UMC - Location VUmc

Amsterdam, North Holland, 1081 HV, Netherlands

RECRUITING

MeSH Terms

Conditions

Pancreatic Neoplasms

Condition Hierarchy (Ancestors)

Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Endocrine Gland Neoplasms; Digestive System Diseases; Pancreatic Diseases; Endocrine System Diseases

Central Study Contacts

Danielle J.W. Vos

CONTACT

+31204444571; d.vos@amsterdamumc.nl

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Study Record Dates

• First Submitted: January 26, 2026
• First Posted: May 19, 2026
• Study Start: June 4, 2023
• Primary Completion (Estimated): June 1, 2026
• Study Completion (Estimated): June 1, 2026
• Last Updated: May 22, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

NL (1)